- Home
- CHEB vs ZOM Comparison
CHEB vs ZOM Comparison
Compare CHEB & ZOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEB
- ZOM
- Stock Information
- Founded
- CHEB 2024
- ZOM 2015
- Country
- CHEB Singapore
- ZOM United States
- Employees
- CHEB N/A
- ZOM N/A
- Industry
- CHEB
- ZOM Biotechnology: Pharmaceutical Preparations
- Sector
- CHEB
- ZOM Health Care
- Exchange
- CHEB NYSE
- ZOM Nasdaq
- Market Cap
- CHEB 119.4M
- ZOM 128.4M
- IPO Year
- CHEB 2024
- ZOM N/A
- Fundamental
- Price
- CHEB $10.12
- ZOM $0.13
- Analyst Decision
- CHEB
- ZOM
- Analyst Count
- CHEB 0
- ZOM 0
- Target Price
- CHEB N/A
- ZOM N/A
- AVG Volume (30 Days)
- CHEB 28.3K
- ZOM 8.2M
- Earning Date
- CHEB 01-01-0001
- ZOM 11-07-2024
- Dividend Yield
- CHEB N/A
- ZOM N/A
- EPS Growth
- CHEB N/A
- ZOM N/A
- EPS
- CHEB N/A
- ZOM N/A
- Revenue
- CHEB N/A
- ZOM $26,727,000.00
- Revenue This Year
- CHEB N/A
- ZOM $10.28
- Revenue Next Year
- CHEB N/A
- ZOM $28.00
- P/E Ratio
- CHEB N/A
- ZOM N/A
- Revenue Growth
- CHEB N/A
- ZOM 11.33
- 52 Week Low
- CHEB $9.96
- ZOM $0.12
- 52 Week High
- CHEB $26.25
- ZOM $0.20
- Technical
- Relative Strength Index (RSI)
- CHEB N/A
- ZOM 50.93
- Support Level
- CHEB N/A
- ZOM $0.13
- Resistance Level
- CHEB N/A
- ZOM $0.16
- Average True Range (ATR)
- CHEB 0.00
- ZOM 0.01
- MACD
- CHEB 0.00
- ZOM -0.00
- Stochastic Oscillator
- CHEB 0.00
- ZOM 27.44
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.
About ZOM Zomedica Corp.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.